Immunogenicity of two-dose sinopharm BBIB-CorV vaccine in Morocco: One-year follow-up and neutralizing activity against severe acute respiratory syndrome coronavirus 2 variants of concern

IF 3.1 4区医学 Q3 IMMUNOLOGY Immunity, Inflammation and Disease Pub Date : 2024-11-12 DOI:10.1002/iid3.1359

Maha Ouarab, Elarbi Bouaiti, Zineb Rhazzar, Hicham El Annaz, Safae el kochri, Mouhssine Hemlali, Hamza Ghammaz, Omar Nyabi, Karim el Bakkouri, Nadia Touil, Mostafa Elouennass, Lamiae Belayachi, Jean Luc Gala, Khalid Ennibi, Elmostafa El Fahime

{"title":"Immunogenicity of two-dose sinopharm BBIB-CorV vaccine in Morocco: One-year follow-up and neutralizing activity against severe acute respiratory syndrome coronavirus 2 variants of concern","authors":"Maha Ouarab, Elarbi Bouaiti, Zineb Rhazzar, Hicham El Annaz, Safae el kochri, Mouhssine Hemlali, Hamza Ghammaz, Omar Nyabi, Karim el Bakkouri, Nadia Touil, Mostafa Elouennass, Lamiae Belayachi, Jean Luc Gala, Khalid Ennibi, Elmostafa El Fahime","doi":"10.1002/iid3.1359","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>This study aimed to evaluate the immunogenicity of a two-dose Sinopharm BBIB-CorV (Vero cells) vaccine against SARS-CoV-2, at 28 days, 6 months, and 1-year postvaccination. And assess the capacity of two-dose vaccine recipients to neutralize SARS-CoV-2 strains B.1 (Wuhan/D614G), B.1.1.7 (Alpha), AY.33 (Delta), or BA.5.2.2 (Omicron) variants of concern (VOCs).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A prospective matched case–control cohort study was conducted at the Military Hospital of Rabat, Morocco between February 2021 and 2022. Immunogenicity was evaluated by standard Microneutralization (MN) assay against four variants (Wuhan D614G, Alpha, Delta, and Omicron).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The overall positive neutralizing rates for vaccine recipients against B.1 D614G were 72.09%, 74.82%, and 75.19% on 28-, 180-, 365- day respectively. The proportion of NAbs targeting the Wuhan D614G, and Alpha variants under the BBIBP-CorV vaccination was high on Day 28- and 6 months postvaccination.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The immunogenic response to the newly emerging SARS-CoV-2 variants of concern (VOCs), such as Delta and Omicron was comparatively reduced. As a result, it is recommended that additional boost vaccinations be considered.</p>\n </section>\n </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"12 11","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555486/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunity, Inflammation and Disease","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iid3.1359","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

This study aimed to evaluate the immunogenicity of a two-dose Sinopharm BBIB-CorV (Vero cells) vaccine against SARS-CoV-2, at 28 days, 6 months, and 1-year postvaccination. And assess the capacity of two-dose vaccine recipients to neutralize SARS-CoV-2 strains B.1 (Wuhan/D614G), B.1.1.7 (Alpha), AY.33 (Delta), or BA.5.2.2 (Omicron) variants of concern (VOCs).

Methods

A prospective matched case–control cohort study was conducted at the Military Hospital of Rabat, Morocco between February 2021 and 2022. Immunogenicity was evaluated by standard Microneutralization (MN) assay against four variants (Wuhan D614G, Alpha, Delta, and Omicron).

Results

The overall positive neutralizing rates for vaccine recipients against B.1 D614G were 72.09%, 74.82%, and 75.19% on 28-, 180-, 365- day respectively. The proportion of NAbs targeting the Wuhan D614G, and Alpha variants under the BBIBP-CorV vaccination was high on Day 28- and 6 months postvaccination.

Conclusion

The immunogenic response to the newly emerging SARS-CoV-2 variants of concern (VOCs), such as Delta and Omicron was comparatively reduced. As a result, it is recommended that additional boost vaccinations be considered.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

摩洛哥两剂国药集团 BBIB-CorV 疫苗的免疫原性：一年随访和针对严重急性呼吸系统综合征冠状病毒 2 变异株的中和活性。

研究背景本研究旨在评估国药集团 BBIB-CorV (Vero 细胞) 两剂疫苗在接种后 28 天、6 个月和 1 年对 SARS-CoV-2 的免疫原性。并评估两剂疫苗接种者中和 SARS-CoV-2 株 B.1（武汉/D614G）、B.1.1.7（阿尔法）、AY.33（德尔塔）或 BA.5.2.2（奥米克隆）变异株（VOCs）的能力：2021 年 2 月至 2022 年 2 月期间，摩洛哥拉巴特军事医院开展了一项前瞻性匹配病例对照队列研究。方法：2021 年 2 月至 2022 年 2 月期间，在摩洛哥拉巴特军事医院开展了一项前瞻性匹配病例对照队列研究，针对四种变异株（武汉 D614G、Alpha、Delta 和 Omicron）采用标准微中和（MN）检测法评估免疫原性：28 天、180 天和 365 天，疫苗接种者对 B.1 D614G 的总体阳性中和率分别为 72.09%、74.82% 和 75.19%。接种BBIBP-CorV疫苗后第28天和6个月，针对武汉D614G和Alpha变体的NAbs比例较高：结论：对新出现的 SARS-CoV-2 变异株（VOCs）（如 Delta 和 Omicron）的免疫原反应相对较低。因此，建议考虑进行额外的强化免疫接种。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Immunity, Inflammation and Disease Medicine-Immunology and Allergy

CiteScore

3.60

自引率

0.00%

发文量

146

审稿时长

8 weeks

期刊介绍： Immunity, Inflammation and Disease is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research across the broad field of immunology. Immunity, Inflammation and Disease gives rapid consideration to papers in all areas of clinical and basic research. The journal is indexed in Medline and the Science Citation Index Expanded (part of Web of Science), among others. It welcomes original work that enhances the understanding of immunology in areas including: • cellular and molecular immunology • clinical immunology • allergy • immunochemistry • immunogenetics • immune signalling • immune development • imaging • mathematical modelling • autoimmunity • transplantation immunology • cancer immunology